Nkarta, Inc. Stock price

Equities

NKTX

US65487U1088

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 12:54:56 2024-03-28 pm EDT 5-day change 1st Jan Change
10.82 USD -2.44% Intraday chart for Nkarta, Inc. -16.80% +63.64%
Sales 2024 * - Sales 2025 * - Capitalization 781M
Net income 2024 * -108M Net income 2025 * -131M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-5.27 x
P/E ratio 2025 *
-5.02 x
Employees 150
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.68%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Nkarta, Inc.

1 day+12.31%
1 week-13.33%
Current month-8.24%
1 month-3.10%
3 months+106.42%
6 months+555.92%
Current year+67.95%
More quotes
1 week
8.47
Extreme 8.47
11.44
1 month
8.47
Extreme 8.47
16.24
Current year
5.37
Extreme 5.3717
16.24
1 year
1.28
Extreme 1.28
16.24
3 years
1.28
Extreme 1.28
40.64
5 years
1.28
Extreme 1.28
79.16
10 years
1.28
Extreme 1.28
79.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 18-01-31
Director of Finance/CFO - 23-07-04
Chief Tech/Sci/R&D Officer 61 16-08-31
Members of the board TitleAgeSince
Director/Board Member 61 20-04-26
Chief Executive Officer 64 18-01-31
Director/Board Member 57 19-07-31
More insiders
Date Price Change Volume
24-03-28 10.81 -2.50% 382 378
24-03-27 11.08 +12.31% 2,624,528
24-03-26 9.87 -5.91% 2,030,545
24-03-25 10.49 +17.60% 4,832,727
24-03-22 8.92 -31.28% 3,384,998

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Nkarta, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies to treat cancer. The Company's product candidates include NKX101 and NKX019, which are in ongoing Phase I clinical trials. NKX101 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy donors. It is engineered with a chimeric antigen receptor (CAR) targeting NKG2D ligands on tumor cells. NKX019 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors. It is engineered with a humanized CD19-directed CAR for enhanced tumor cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
11.08 USD
Average target price
19.25 USD
Spread / Average Target
+73.66%
Consensus
  1. Stock
  2. Equities
  3. Stock Nkarta, Inc. - Nasdaq